Business Context and Reporting Period
This Form 8-K was filed by Halozyme Therapeutics, Inc. on October 28, 2004, reporting events that occurred on October 22, 2004. The company is incorporated in Nevada and maintains its principal executive offices in San Diego, California.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial statements. Consequently, there is no data provided regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Listing Transfer Approval: The American Stock Exchange (AMEX) approved the Company's application to transfer the listing of its securities from the OTC Bulletin Board.
- Trading Commencement: Securities are expected to begin trading on the AMEX on November 1, 2004.
- Symbol Change: The stock trading symbol will change to "HTI".
Guidance, Outlook, and Risks
The filing references a press release dated October 25, 2004, but does not include specific management commentary, financial guidance, risk factors, or contingencies within the text of this report. The primary focus is the administrative change in listing venue.
Investor Verification Checklist
- Verify the commencement of trading under the new symbol HTI on the AMEX on November 1, 2004.
- Review the attached Press Release (Exhibit 99.1) for additional details on the listing transfer.
- Confirm the removal of the stock from the OTC Bulletin Board concurrent with the AMEX listing.